Latest news

• Pricing pressures peg back Lilly’s growth products

  Lilly was still able to post modest sales growth of 3% to $5.1bn, despite the ongoing impact of generic competition to its big-selling erectile dysfunction drug Cialis (tadalafil), but

• FDA approves Sanofi's follow-on version of Lilly’s Humalog

  Humalog is just one of Lilly’s big brands facing competition, along with erectile dysfunction therapy Cialis (tadalafil) and antiplatelet drug Effient (prasugrel), and the company recently announced sweeping job cuts

• Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

  Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

• Lilly pilots enhanced online trial information

  The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with

• GSK earns expanded approval for Volibris in Europe

  But, the decision is based on data from the phase III/IV AMBITION study, which showed that the combination of Volibris (ambrisentan) and tadalafil reduced the risk of clinical failure by ... 50% in treatment-naïve PAH patients compared to pooled